HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients.

AbstractBACKGROUND:
The implantable cardioverter-defibrillator (ICD) prevents sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy (HCM). However, recently concerns have been raised regarding the performance of transvenous high-voltage ICD leads (HVL) in this population.
OBJECTIVE:
The purpose of this retrospective, multicenter study was to assess the safety and efficacy of HVL in high-risk HCM patients.
METHODS:
The study population consisted of HCM patients who received HVL ICDs and were subsequently followed at seven centers in the United States. Kaplan-Meier survival rates were calculated for HVL and patients. HVL failure was a malfunction caused by a noniatrogenic defect.
RESULTS:
Between 1992 and 2007, 324 HCM patients (mean age 47 +/- 16 years) received 343 HVL from three major manufacturers. The average HVL implant duration was 3.3 +/- 2.8 years. Overall, the HVL failure rate was 1.4%/year. However, two models (Sprint Fidelis and Transvene, Medtronic, Inc.) accounted for 60% of HVL failures. Survival probabilities for HVL and patients at 10 years were 93% and 91%, respectively. No deaths or serious injuries were reported, although inappropriate shocks occurred in 12% of cases.
CONCLUSIONS:
This multicenter experience shows that HVLs are safe and effective in high-risk HCM patients. However, differences in failure rates were found between lead models.
AuthorsRobert G Hauser, Barry J Maron, Joseph E Marine, Rachel Lampert, Alan H Kadish, Stephen L Winters, David L Scher, Mazda Biria, Amit Kalia
JournalHeart rhythm (Heart Rhythm) Vol. 5 Issue 11 Pg. 1517-22 (Nov 2008) ISSN: 1556-3871 [Electronic] United States
PMID18984525 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Topics
  • Adult
  • Cardiomyopathy, Hypertrophic (therapy)
  • Defibrillators, Implantable
  • Equipment Failure
  • Equipment Safety
  • Female
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: